logo
welcome
Reuters

Reuters

Evotec and Novo Nordisk in technology development partnership

Reuters
Summary
Nutrition label

83% Informative

Evotec will receive funding for technology development activities in Germany and Italy , research and development funding, an undisclosed upfront payment and possible milestone and royalty payments.

Stem cell-based therapies at Novo Nordisk are still at an exploratory level within diabetes and cardiovascular diseases.

VR Score

92

Informative language

97

Neutral language

81

Article tone

formal

Language

English

Language complexity

75

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links